Lymphocyte cytotoxicity in bladder cancer. No requirement for thymus-derived effector cells?
D000818:Animals; D000918:Antibody Specificity; D000961:Antilymphocyte Serum; D002295:Carcinoma, Transitional Cell / Q000276:immunology* / Q000532:radiotherapy; D002478:Cells, Cultured; D003601:Cytotoxicity Tests, Immunologic; D006801:Humans; D007111:Immunity, Cellular; D011817:Rabbits / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000532:radiotherapy
D000961:Antilymphocyte Serum